German construction sector still in recession, civil engineering only bright spot
Investing.com -- Immuneering Corporation (NASDAQ:IMRX) stock surged 50% after the company announced exceptional survival data from its Phase 2a trial of atebimetinib combined with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients.
The clinical-stage oncology company reported an 86% overall survival rate at 9 months among the 34 patients in the trial, significantly outperforming the standard of care benchmark of approximately 47%. The progression-free survival rate at 9 months was 53%, compared to the standard care benchmark of about 29%.
The trial results represent a potential breakthrough for pancreatic cancer, one of the deadliest and most treatment-resistant solid tumors. Immuneering’s atebimetinib, a Deep Cyclic Inhibitor, targets MEK, a key control point in the MAPK pathway that is pathologically activated in approximately 97% of pancreatic cancers.
"I have seen firsthand in my own patients the benefits of atebimetinib’s durability and tolerability," said Vincent Chung, Professor at City of Hope and principal investigator of the Phase 2a clinical trial, who also serves as a paid member of the company’s scientific advisory board.
The company reported a favorable tolerability profile, with only two categories of adverse events observed at the Grade 3 level in more than 10% of patients - neutropenia and anemia - both commonly observed with standard chemotherapy treatments.
Immuneering expects regulatory feedback on pivotal trial plans in Q4 2025 and aims to initiate a pivotal trial by the end of 2025, with patient dosing expected by mid-2026.
In a separate announcement, the company disclosed plans for a public offering of Class A common stock and revealed that Sanofi has agreed to purchase $25 million of Immuneering’s shares in a private placement transaction expected to close concurrently with the public offering.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.